Literature DB >> 18096994

Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen.

Christopher C Valley1, Natalia M Solodin, Ginny L Powers, Stephanie J Ellison, Elaine T Alarid.   

Abstract

Estrogen receptor-alpha (ERalpha) is essential in the maintenance of cellular responsiveness to estrogen in the reproductive system. It is established that ligand binding induces downregulation of ERalpha protein by targeting receptor for destruction by the 26S proteasome. However, ERalpha is preserved in cells chronically exposed to estrogen and it is unknown how receptor levels are maintained in the continued presence of the signal that induces degradation. A modified pulse-chase analysis was developed using a tet-inducible ERalpha expression system to determine the rate of ERalpha protein decay following both acute and chronic estrogen treatments. Upon initial hormone treatment, ERalpha half-life is shortened from 3 to 1 h. However, ERalpha half-life increases over time, achieving a half-life of approximately 6 h in 72 h of estrogen treatment. Analysis of ERalpha half-life in the presence and absence of proteasome inhibitor, MG132, revealed that the increased stability is due in part to a decreased rate of proteolysis. In addition, we observed a time-dependent increase in phospho-S118 ERalpha and showed that the half-life of the phosphomimetic ERalpha mutant, S118E-ER, is identical to that of wild-type receptor under conditions of chronic estrogen treatment. These data provide evidence that as cells adapt to chronic stimulation, ERalpha protein is stabilized due first to a decreased rate of proteolysis, and secondarily, to the accumulation of proteasome-resistant, phosphorylated form of receptor. This temporal control of proteolysis allows for the establishment of steady-state levels of receptor and provides a protective mechanism against loss of hormone responsiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18096994     DOI: 10.1677/JME-07-0067

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  26 in total

1.  Implantation failure in mice with a disruption in Phospholipase C beta 1 gene: lack of embryonic attachment, aberrant steroid hormone signalling and defective endocannabinoid metabolism.

Authors:  Panayiotis Filis; Peter C Kind; Norah Spears
Journal:  Mol Hum Reprod       Date:  2013-01-07       Impact factor: 4.025

2.  C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection.

Authors:  Quan-guang Zhang; Dong Han; Rui-min Wang; Yan Dong; Fang Yang; Ratna K Vadlamudi; Darrell W Brann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

3.  Hypoxia differentially regulates estrogen receptor alpha in 2D and 3D culture formats.

Authors:  Nathan A Whitman; Zhi-Wei Lin; Rachael M Kenney; Leonardo Albertini; Matthew R Lockett
Journal:  Arch Biochem Biophys       Date:  2019-06-01       Impact factor: 4.013

Review 4.  Long-term consequences of estrogens administered in midlife on female cognitive aging.

Authors:  Jill M Daniel; Christine F Witty; Shaefali P Rodgers
Journal:  Horm Behav       Date:  2015-04-25       Impact factor: 3.587

5.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

6.  Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.

Authors:  Stephanie J Ellison-Zelski; Elaine T Alarid
Journal:  Mol Cancer       Date:  2010-09-29       Impact factor: 27.401

7.  Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Authors:  Stephanie J Ellison-Zelski; Natalia M Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

Review 8.  Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors:  Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

9.  Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity.

Authors:  Jessica D Lang; Scott M Berry; Ginny L Powers; David J Beebe; Elaine T Alarid
Journal:  Integr Biol (Camb)       Date:  2013-05       Impact factor: 2.192

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.